rNAPc2

ARCA Biopharma, Inc. · Phase 2 active Small molecule

At a glance

Generic name	rNAPc2
Also known as	AB201, Recombinant Nematode Anticoagulant Protein c2
Sponsor	ARCA Biopharma, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (PHASE2, PHASE3)
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer (PHASE1, PHASE2)
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

rNAPc2 CI brief — competitive landscape report
rNAPc2 updates RSS · CI watch RSS
ARCA Biopharma, Inc. portfolio CI